Benzinga (Video) on MSN21h
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst ReactionsAmgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Investor's Business Daily on MSN1d
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity ShotAmgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback